Pharmaceuticals company Innova Captab announced Q3FY25 results Revenue from Operations was Rs 316.5 crore in Q3FY25 vs Rs 302.5 crore Q3FY24, registering growth of 4.6%. EBITDA grew to Rs 50.9 crore vs Rs 46.9 crore last year. EBITDA Margins also improved to 16.1% vs 15.5% in Q3FY24. Profit after Tax improved significantly to Rs 34.2 crore vs Rs 25.1 crore (YoY growth of 36.3%). PAT Margins improved to 10.8% from 8.3%. Vinay Lohariwala, Managing Director, Innova Captab, said: “We are delighted to report a healthy performance in Q3 and 9MFY25, driven by robust resilience in our core business operations and strategic advancements. Our revenue from operations registered YoY growth of 4.6% in Q FY25 and of 13.5% in 9MFY25. PAT demonstrated strong surge of 36.3% in Q3FY25 and of 50.5% in 9MFY25. Key highlight of the quarter was the successful launch of operations at our new Kathua, Jammu facility, where we commenced commercial production on January 14, 2025. This milestone represents a pivotal moment in our growth trajectory, bolstering both our production capacity and our ability to meet the evolving demands of our customers. This expansion is a cornerstone of our long-term strategic vision, reinforcing our market position and laying the foundation for sustained, profitable growth. With the added advantage of incentives from the central government, we are optimistic about the positive impact on profitability from the Jammu operations. As we look to the future, we are confident in the continued strength and resilience of our business. With a diversified portfolio and a steadfast commitment to long-term value creation, our teams are united in executing our strategic priorities. We are well-positioned for sustained growth and are excited to build on this momentum in the years ahead.” Result PDF
Pharmaceuticals company Innova Captab announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from Operations was Rs 318.2 crore in the quarter vs Rs 282.9 crore last year, registering growth of 12.5%. EBITDA grew to Rs 51.9 crore vs Rs 43.8 crore last year. EBITDA Margins also improved to 16.3% vs 15.5% in Q2FY24. Profit after Tax improved significantly to Rs 35.0 crore vs Rs 22.9 crore (YoY growth of 52.8%). PAT Margins improved to 11.0% from 8.1%. H1FY25 Financial Highlights: Revenue from Operations grew 18.7% to Rs 612.5 crore vs Rs 516.2 crore during H1FY24. EBITDA increased to Rs 96.2 crore vs Rs 76.2 crore (YoY improvement of 26.2%). EBITDA margins improved by 90 bps to 15.7%. Profit after Tax grew by 59.2% to Rs 64.5 crore vs Rs 40.5 crore in H1FY24. PAT Margin increased to 10.5% from 7.8%. Vinay Lohariwala, Managing Director, Innova Captab, said: “As we reflect on our Q2 and first half results for FY25, we are proud to report that our strategic initiatives are yielding tangible growth across all business areas, with a significant improvement in overall profitability. In Q2 FY25, we achieved YoY revenue growth of 12.5%, while H1FY25 saw an impressive increase of 18.7%. Our PAT demonstrated remarkable growth, with YoY growth of almost 53% in Q2 FY25 and 59% in H1FY25. We are particularly excited about the progress at our greenfield plant in Jammu, where we recently received ‘Drug Manufacturing License’ from Government of Jammu and Kashmir, Department of Health and Medical Education, Drug Control Organization, Jammu. With other necessary approvals in place, we had already begun manufacturing validation/ trial batches, and now with the receipt of the license, we expect commercialization of the facility within Q3FY25. Additionally, we are establishing a new R&D; facility in Panchkula, Haryana, which will further enhance our innovation capabilities. Over the past few years, we have consistently demonstrated a high growth trajectory. With these initiatives and by leveraging our existing strengths, we are confident to continue to build growth momentum. We would like to thank our dedicated team and valued stakeholders for their ongoing support as we strive to create a sustainable and prosperous future for our company.” Result PDF
Pharmaceuticals company Innova Captab announced Q1FY25 results: Revenue from operation is Rs 294.3 crore in Q1FY25 as against Rs 233.2 crore of Q1FY24 registering a growth of 26%. The Company’s EBITDA stood at Rs 44.3 crore in Q1FY25 against Rs 32.4 crore of Q1FY24 registering a growth of 37%. Profit After Tax (PAT) stood at Rs 29.5 crore in Q1FY25 against Rs 17.6 crore of Q1FY24 registering a growth of 68% Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab said, For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters. Over the past 3-4 years, our revenue has grown at a robust growth rate. With the new Jammu facility, we are optimistic about sustaining this growth trajectory over the next few years. As a company, we remain committed to driving sustainable growth by exploring new opportunities and focusing on value-added products. The Indian pharmaceutical sector is poised for significant growth in the mid to long term, with both domestic and global MNCs are increasingly seeking reliable and sustainable suppliers like us. The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India’s top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities. By Q2FY25, the upcoming greenfield plant in Jammu is expected to be commercialized. This facility will have four production blocks: cephalosporin, penicillin, penum and BFS and will manufacture oral solid dosages, dry powder injections, dry syrup, BFS, Large Volume Parenterals and respiratory respule products. Result PDF
Conference Call with Innova Captab Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Innova Captab announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from operation is Rs 262.63 crore in Q4FY24 as against Rs 240.95 crore of previous year registering a growth of 9.0%. The Company’s EBITDA stood at Rs 43.76 crore in Q4FY24 against Rs 29.42 crore of previous year registering a growth of 48.7%. Profit After Tax (PAT) stood at Rs 28.72 crore in Q4FY24 against Rs 17.25 crore of previous year registering a growth of 66.5%. FY24 Financial Highlights: Total Income for the FY24 stood at Rs 1,093.79 crore against Rs 935.58 crore in FY23 with growth of 16.9% over FY23. Revenue from Operation has increased to Rs 1,081.31 crore in FY24 from Rs 926.38 crore in FY23, registering a growth of 16.7%. The Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) stands at Rs 166.94 crore in FY24, as against Rs 122.85 crore in FY23, with an increase of 35.9%. Profit After Tax (PAT) is Rs 94.35 crore in FY24 as against Rs 67.95 crore in FY23, registering a growth of 38.9%. Earnings per share (EPS) for FY24 is Rs 18.66, against Rs 14.16 in FY23 For FY24, net cash generated from operating activities stood at Rs 146 crore, against Rs 67 crore in FY23. Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab Limited said, For FY24, we reported a total income of Rs 1,094 crore with a growth of 16.9% compared to the previous year. Our all business areas are getting good traction and are expected to grow at a healthy rate in the coming years. Over the last 3-4 years, we have grown at a healthy rate of ~ 20% CAGR. With our upcoming Jammu facility and recent Sharon acquisition, we are positively looking forward to maintaining the same healthy growth rate over the next 3-4 years. As a company we continue to drive sustainable growth by exploring new opportunities and focusing on value-added products. Indian pharmaceutical companies are set to experience significant growth in the mid to long term, as both domestic and global manufacturers seek reliable and sustainable suppliers like us. Result PDF